

Editorial Note

Editorial Note for *Santen Report 2024*

Thank you for taking the time to read *Santen Report 2024*.

With the completion of the structural reforms carried out mainly in fiscal 2023, and the faster-than-expected progress of medium-term management plan initiatives, Santen is now placing greater focus on building the foundation for medium- to long-term growth.

In last year’s report we reviewed and renewed our value creation process. This year, we showcase it through a vertical page layout (as used for the introductory pages and front cover), making the flow of that process more visually intuitive. Commercial Excellence is one of Santen’s strengths. In that regard, the report talks about our business strategy overseas, primarily in the message from the COO, and also discusses new product areas that will be essential for our growth. From the viewpoint of sustainability, we cover our approach to people development and promotion in our human capital initiatives. Regarding the environment, we detail our biodiversity policy, as well as our efforts toward decarbonization and waste reduction.

- The color palettes used in this report comply with accessibility guidelines for readers with color vision impairments.
- We are creating Daisy audiobook versions on Sapie, a comprehensive network of information for the visually impaired.

We also introduce examples of digital transformation and how we share our CORE PRINCIPLE. On governance, we feature a dialogue between an Outside Director and a Corporate Officer (Global Head of Corporate Strategy), covering our approaches to human resources and risk management.

Each department worked with the CEO and the management team to create content for this report. This content takes the opinions received in our dialogue with investors and stakeholders, as well as various guidelines, into account. I assure you that this integrated report was appropriately prepared and that its contents are accurate. I hope that in reading this report, you will gain a better understanding of our thoughts on our business and our approach to sustainability.

Takahiro Morita

Corporate Officer,
Global Head of Core Principle & Sustainability

August 2024

<i>Santen Report 2024</i> Production Members (alphabetical order)	Investor Relations/Sustainability S. Akao, K. Harada, M. Inoue, K. Itagaki, S. Kajiya, M. Nitta, G. Sakuma, A. Tanaka, M. Yoshida
---	---

Editorial Policy

Santen’s integrated report provides a view of overall business activities based on its CORE PRINCIPLE. The report is edited with the intention of informing stakeholders about the value Santen provides to customers and society and includes comprehensive coverage of financial information as well as non-financial information such as management strategies, review of operations, and sustainability activities. Santen has streamlined content and simplified descriptions to allow for easier understanding by a wide range of stakeholders, starting with shareholders and investors. Detailed information is available on the global corporate website.

Applicable Scope

Santen Pharmaceutical Co., Ltd. and consolidated subsidiaries
Country/Regional classifications are based on Santen’s business operations.

Reporting Period

Fiscal 2023 (April 1, 2023 to March 31, 2024)
Certain information is updated after April 1, 2024.

Concerning Forward-Looking Statements

This report contains forward-looking statements regarding the Company’s plans, strategies, and results for the future. All forward-looking statements are based on judgments derived from the information available to the Company at the time of publication. Certain risks and uncertainties could cause the Company’s actual results to differ materially from any projections presented in this report. These risks and uncertainties include, but are not limited to, adverse economic conditions, delays in new product launches, currency exchange rates, legislative and regulatory developments.

This report contains information about pharmaceutical products (including products under development), but such information is not for the purpose of advertising or medical advice.

The following are registered trademarks of Santen’s partner companies.

- Alesion (Boehringer Ingelheim KG)
- Cravit (Daiichi Sankyo Co., Ltd.)
- EYLEA (Bayer AG)
- Rocklatan, Roclanda, Rhopressa, Rhokiinsa (Alcon Inc.)

Reference Guidelines

The International Integrated Reporting Framework (International Integrated Reporting Council/IFRS Foundation), The GRI Sustainability Reporting Standards (Global Reporting Initiative), Environmental Reporting Guidelines (Japan’s Ministry of the Environment) and Guidance for Integrated Corporate Disclosure and Company-Investor Dialogue for Collaborative Value Creation 2.0 (Japan’s Ministry of Economy, Trade and Industry)



The *Santen Report* and Santen’s Information Disclosure Framework

In the *Santen Report* (this document), we publish information each fiscal year on topics that we consider particularly useful to investors. For more detailed or other relevant information, please see the global corporate website.

Detailed Information

